KEYNOTE-028 [104] was a multicohort, nonrandomized, phase Ib trial that enrolled PD-L1-positive relapsed/metastatic NPC patients after chemotherapy progression. The gene discussed is CD274; the disease is nasopharyngeal carcinoma.